Characterization of two polymorphs of lornoxicam

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 1, 2013, Pages 44-52

  Zhang, Jianjun ^a   Tan, Xin ^a   Gao, Jing ^b   Fan, Weiming ^c   Gao, Yuan ^b   Qian, Shuai ^d  

^a Department of Pharmaceutics ^*  (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c ZheJiang Zhenyuan Pharmaceutical Co Ltd   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

dissolution; lornoxicam; polymorphs; solubility

Indexed keywords

LORNOXICAM;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG POLYMORPHISM; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; IN VITRO STUDY; INFRARED SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; THERMAL ANALYSIS; THERMOGRAVIMETRY; X RAY POWDER DIFFRACTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DIFFUSION; HYDROGEN BONDING; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR STRUCTURE; PIROXICAM; POWDER DIFFRACTION; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STEREOISOMERISM; THERMOGRAVIMETRY;

EID: 84870862049     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01573.x     Document Type: Article

References (39)

1. Matsuoka M, et al,. Polymorphism, morphologies and bulk densities of DL-methionine agglomerate crystal. J Cryst Growth 1999; 198: 1299-1306.
2. Pudipeddi M, Serajuddin AT,. Trends in solubility of polymorphs. J Pharm Sci 2005; 94: 929-939.
3. Tuladhar MD, et al,. Thermal behaviour and dissolution properties of phenylbutazone polymorphs. J Pharm Pharmacol 1983; 35: 208-214.
4. Heinz A, et al,. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy. J Pharm Pharmacol 2009; 61: 971-988.
5. Banga S, et al,. Modification of the crystal habit of celecoxib for improved processability. J Pharm Pharmacol 2007; 59: 29-39.
6. Markel AL, et al,. Effects of the alpha- and gamma-polymorphs of glycine on the behavior of catalepsy prone rats. Pharmacol Biochem Behav 2011; 98: 234-240.
7. Balfour JA, et al,. Lornoxicam, a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996; 51: 639-657.
8. Berg J, et al,. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/2 inducible nitric oxide (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res 1999; 48: 369-379.
9. Rosenow DE, et al,. A comparison of patient controlled analgesia with lornoxicam versus morphine in patients undergoing lumbar disk surgery. Anesth Analg 1998; 86: 1045-1050.
10. Radhofer-Welte S, Rabasseda X,. Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today 2000; 36: 55-76.
11. Hitzenberger G, et al,. Pharmacokinetics of lornoxicam in man. Postgrad Med J 1990; 66: 22-26.
12. Radhofer-Welte S, et al,. Comparative bioavailability of lornoxicam as single doses of quick-release tablet, standard tablet and intramuscular injection: a randomized, open-label, crossover phase I study in healthy volunteers. Clin Drug Investig 2008; 28: 345-351.
13. Møller PL, Nørholt SE,. Analgesic efficacy of quick-release versus standard lornoxicam for pain after third molar surgery: a randomized, double-blind, placebo-controlled, single-dose trial. Clin Drug Investig 2008; 28: 757-766.
14. Saricaoglu F, et al,. Effect of intra articular injection of lornoxicam on the articular cartilage & synovium in rat. Indian J Med Res 2008; 127: 362-365.
15. Vrecer F, et al,. Characterization of piroxicam crystal modifications. Int J Pharm 2003; 256: 3-15.
16. Sheth AR, et al,. Polymorphism in piroxicam. Cryst Growth Des 2004; 4: 1091-1098.
17. Ghan GA, Lalla JK,. Effect of compressional forces on piroxicam polymorphs. J Pharm Pharmacol 1992; 44: 678-681.
18. Cantera RG, et al,. Solid phases of tenoxicam. J Pharm Sci 2002; 91: 2240-2251.
19. Salem MS, et al,. Bioequivalence of two oral dosage forms prepared from different polymorphic modifications of tenoxicam. J Clin Pharm Ther 1994; 19: 203-207.
20. Cheney ML, et al,. Supramolecular architectures of meloxicam carboxylic acid cocrystals, a crystal engineering case study. Cryst Growth Des 2010; 10: 4401-4413.
21. Fan W, et al,. Synthesis of lornoxicam. Chin J Pharm 2002; 33: 365-366.
22. Gao Y, et al,. Enhanced dissolution and stability of adefovir dipivoxil by cocrystal formation. J Pharm Pharmacol 2011; 63: 483-490.
23. Guguta C, et al,. Crystal structure of aspartame anhydrate from powder diffraction data. structural aspects of the dehydration process of aspartame. Cryst Growth Des 2006; 6: 2686-2692.
24. Baka E, Takács-Novák K,. Study on standardization of shake-flask solubility determination method. Eur J Pharm Sci 2007; 32: 23-24.
25. Zhang J, et al,. Development and validation of a stability indicating HPLC method for the analysis of lornoxicam in powder for injection. Pak J Pharm Sci 2002; 25: 371-375.
26. Mishra BK, Sathyamurthy N,. π-π Interaction in pyridine. J Phys Chem A 2005; 109: 6-8.
27. Cheng WT, Lin SY,. Famotidine polymorphic transformation in the grinding process significantly depends on environmental humidity or water content. Int J Pharm 2008; 357: 164-168.
28. Chieng N, et al,. Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1. Int J Pharm 2006; 327: 36-44.
29. Agafonov V, et al,. Polymorphism of spironolactone. J Pharm Sci 1991; 80: 181-185.
30. Martínez F, et al,. Thermodynamic study of the solubility of some sulfonamides in cyclohexane. J Braz Chem Soc 2003; 14: 803-808.
31. Gracin S, Rasmuson AC,. Solubility of phenylacetic acid, p-hydroxyphenylacetic acid, p-aminophenylacetic acid, p-hydroxybenzoic acid, and ibuprofen in pure solvents. J Chem Eng Data 2002; 47: 1379-1383.
32. Bernstein J,. Conformational polymorphism: intra- and intermolecular energetics. In:, Bernstein J, ed. Polymorphism in Molecular Crystals. New York: Oxford Science Publications, 2002: 160-162.
33. Skjodt NM, Davies NM,. Clinical pharmacokinetics of lornoxicam: a short half-life oxicam. Clin Pharmacokinet 1998; 34: 421-428.
34. Ho J, et al,. First-principles prediction of the pK(a)s of anti-inflammatory oxicams. J Phys Chem A 2010; 114: 11992-12003.
35. Rodríguez-Barrientos D, et al,. Determination of pKa values of tenoxicam from 1H NMR chemical shifts and of oxicams from electrophoretic mobilities (CZE) with the aid of programs SQUAD and HYPNMR. Talanta 2009; 80: 754-762.
36. Wu Z, et al,. Physicochemical characterization of ricobendazole: I. solubility, lipophilicity, and ionization characteristics. J Pharm Sci 2005; 94: 983-993.
37. Karabas I, et al,. Analysis and stability of polymorphs in tablets: the case of risperidone. Talanta 2007; 71: 1382-1386.
38. Shin SC, et al,. Enhanced dissolution of furosemide by coprecipitating or cogrinding with crospovidone. Int J Pharm 1998; 175: 17-24.
39. Vogt M, et al,. Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients. Eur J Pharm Biopharm 2008; 68: 330-337.